NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.

Workspace · Cancer algorithms · Urinary bladder

Urinary bladder

Urinary bladder · 84,530 new · 17,870 deaths (ACS 2026) · mortality 4.1 per 100k · 5-yr RS 79.1% (SEER)

Mortality 4.1 per 100k (SEER / ACS common-sites). Never an artboard percent.

Lifetime ≈ 2.1% (SEER Stat Facts). 763,031 people living with bladder cancer in 2023. No encoded screening interval. Mortality is 4.1 per 100k, never an artboard percent.

763,031 people living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.

Median age at diagnosis 73 · at death 79 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.

Incidence men 31.0 / women 7.6 per 100k · mortality men 7.0 / women 2.0 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.

Most often diagnosed among people aged 65–74. Deaths highest among people aged 75–84. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.

New cases falling 1.6% each year (2014–2023). Death rates falling 1.3% each year (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.

Highest new-case rate: Non-Hispanic White men 37.3 per 100k. Highest death rate: Non-Hispanic White men 7.9 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

Race/ethnicity rates per 100k (SEER Stat Facts)

SEER Stat Facts race and ethnicity incidence and mortality per 100k
Group	Inc. men	Inc. women	Deaths men	Deaths women
Hispanic	17.2	4.8	3.6	1.2
Non-Hispanic American Indian/Alaska Native	18.6	5.5	3.8	1.8
Non-Hispanic Asian/Pacific Islander	15.0	3.6	2.7	0.9
Non-Hispanic Black	19.6	6.1	5.1	2.1
Non-Hispanic White	37.3	9.1	7.9	2.2

Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

USPSTF screening pointer

USPSTF 2011 I · Asymptomatic adults · Insufficient evidence — no population program

Cited only. No screening interval and no unpublished coefficient. USPSTF-bladder-2011

ACS early-detection pointer

ACS 2024 · People at average risk of bladder cancer · ACS (2024): major professional organizations do not recommend routine screening for bladder cancer for most people, because screening has not been shown to lower the risk of dying from bladder cancer in people at average risk. Complementary to the cited USPSTF 2011 I statement. Not a urine-marker engine.

Cited ACS statement only. Not a screening engine. ACS-bladder-detect

Surveillance pointer

ACS-bladder-follow 2024 · cited only · ACS living-as-a-survivor page names regular cystoscopy when the bladder has not been removed, plus checks after urinary diversion. Those months are not encoded. Not a cystoscopy-interval engine.

Named public source only. Not a personal follow-up calendar. ACS-bladder-follow

Surveillance pointer

ACS-bladder-follow 2024 · cited only · ACS living-as-a-survivor page says most experts do not recommend additional testing to look for second cancers in people who have had bladder cancer. Complementary to the cystoscopy living-as pointer. Not a second-primary screening engine.

Named public source only. Not a personal follow-up calendar. ACS-bladder-follow

Surveillance pointer

ACS-long-term-effects 2025 · cited only · ACS long-term page names bowel blockage from adhesions after abdomen or pelvis treatment, plus urinary retention, leakage, or UTIs. Those names are not encoded. Complementary to the cystoscopy living-as pointer. Not a cystoscopy-interval engine.

Named public source only. Not a personal follow-up calendar. ACS-long-term-effects

Surveillance pointer

ACS-follow-up-care 2025 · cited only · ACS follow-up-care page, developed with ASCO review, names a treatment summary and survivorship care plan, plus watching for recurrence and for a second cancer. Echoes are named after cardiotoxic chemo. Those plans and tests are not encoded. Complementary to the prostate printout. Death rate stays a rate per 100k. Not a cystoscopy-interval engine.

Named public source only. Not a personal follow-up calendar. ACS-follow-up-care

Toxicity pointer

ACS-bladder-follow 2024 · empty on purpose · ACS living-as-a-survivor page names infection, kidney, and diversion checks after cystectomy. Those late effects are not encoded. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-bladder-follow

Toxicity pointer

ACS-bladder-follow 2024 · empty on purpose · ACS living-as-a-survivor page names later cancers after bladder-cancer treatment. Those second-cancer risks are not encoded. Complementary to the living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-bladder-follow

Toxicity pointer

ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later bowel blockage from adhesions and urinary retention or incontinence after abdomen or pelvis treatment. Those late effects are not encoded. Complementary to the living-as pointer. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-long-term-effects

Toxicity pointer

ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a treatment summary and second-cancer watching after pelvis treatment. Echoes are named after cardiotoxic chemo. Those named tests are not encoded. Complementary to the prostate printout. Death rate stays a rate per 100k. Not a cystoscopy-interval engine. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-follow-up-care

Late toxicity printout

Late toxicity printout — Prostate

Acute: ACS names fatigue, pelvic-field skin change, short-term rectal and bladder problems, and nausea. Late: radiation proctitis and cystitis, incontinence, fertility and sexual side effects, low testosterone, osteoporosis, heart problems after ADT, lasting fatigue, jaw osteonecrosis after bisphosphonates, and vision change after hormone therapy. Monitor: lingering rectal or bladder symptoms after 3 to 6 months; echoes after cardiotoxic chemo; lasting fatigue or sleep problems; dental check before bisphosphonates; vision change after hormone therapy; a treatment summary. Those names are not encoded. First-row prostate toxicity stays empty on purpose. Not a PSA-kinetics or testosterone engine.

Questions to ask

ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.

ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.

ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.

Treatment summary and care plan

ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.

How late effects are managed

ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.

ACS long-term late names

Low testosterone after pelvic treatment or ADT
Osteoporosis after hormone-affecting treatment
Low estrogen or testosterone after hormone-affecting treatment
Osteonecrosis of the jaw after bisphosphonates
Vision change after hormone therapy
Heart problems after ADT
Heart problems after some cardiotoxic treatments
Cancer-related fatigue that lasts
Joint or muscle pain after some treatments
Mental health and distress after treatment

ACS follow-up tests named here

Echoes after cardiotoxic chemo

Named conditions to monitor

Radiation proctitis after 3 to 6 months
Radiation cystitis
PSA after treatment
Bone and heart health after ADT
Bone density after hormone-affecting treatment
Hot flashes, bone loss, or sex-hormone change after hormone-affecting treatment
New heart symptoms years after cardiotoxic treatment
Dental check before bisphosphonates
Vision change after hormone therapy
Cancer-related fatigue or sleep problems that last
Joint or muscle pain after chemo, steroids, or hormone therapy
Anxiety, depression, or fear of recurrence after treatment
Second-cancer awareness after radiation or chemo
Ask which late-effect tests belong on the follow-up plan

Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Cited ACS pelvis / prostate names only. Complementary ACS long-term page is named, not encoded. First-row prostate toxicity stays empty on purpose. No invented trial percent.

Open Prostate printout →

NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.

algo-stub-bladder · stub · none · v2-stub-bladder

SEER 5-year relative survival by stage (cited stub)

In situ 98.0% · Localized 73.0% · Regional 41.8% · Distant 9.6% · All 79.1%

SEER Stat Facts includes in situ as its own band. Mortality stays 4.1 per 100k.

Percent of cases by stage (SEER Stat Facts)

In situ 50% · Localized 34% · Regional 7% · Distant 6% · Unknown 3%

Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage. In situ is its own Stat Facts band. Mortality stays 4.1 per 100k.

lifetime
Bladder birth-to-death
≈ 2.1%

Screening · Surveillance · Toxicity on four golden fixtures

Rio · Plan — survivor

not computed — v2 stub

Cited ACS/SEER population pin only

screening
USPSTF 2011 I — insufficient evidence for a population program
Cited USPSTF 2011 I and ACS 2024 statements. No urine-marker screening engine.
not encoded
surveillance
ACS follow-up cited — cystoscopy months not encoded
Cited ACS living-as-a-survivor page only. Not a cystoscopy-interval engine.
not encoded
toxicity
ACS late effects cited — bladder months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Noah · Plan — skin cancer

not computed — v2 stub

Cited ACS/SEER population pin only

screening
USPSTF 2011 I — insufficient evidence for a population program
Cited USPSTF 2011 I and ACS 2024 statements. No urine-marker screening engine.
not encoded
surveillance
ACS follow-up cited — cystoscopy months not encoded
Cited ACS living-as-a-survivor page only. Not a cystoscopy-interval engine.
not encoded
toxicity
ACS late effects cited — bladder months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Walter · S1 prostate

not computed — v2 stub

Cited ACS/SEER population pin only

screening
USPSTF 2011 I — insufficient evidence for a population program
Cited USPSTF 2011 I and ACS 2024 statements. No urine-marker screening engine.
not encoded
surveillance
ACS follow-up cited — cystoscopy months not encoded
Cited ACS living-as-a-survivor page only. Not a cystoscopy-interval engine.
not encoded
toxicity
ACS late effects cited — bladder months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Priya · average-risk

not computed — v2 stub

Cited ACS/SEER population pin only

screening
USPSTF 2011 I — insufficient evidence for a population program
Cited USPSTF 2011 I and ACS 2024 statements. No urine-marker screening engine.
not encoded
surveillance
ACS follow-up cited — cystoscopy months not encoded
Cited ACS living-as-a-survivor page only. Not a cystoscopy-interval engine.
not encoded
toxicity
ACS late effects cited — bladder months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded

Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.

All cancers →Screening →Surveillance →Toxicity →